Details for Patent: 10,456,396

« Back to Dashboard

Which drugs does patent 10,456,396 protect, and when does it expire?

Patent 10,456,396 protects TYRVAYA and is included in one NDA.

This patent has forty-four patent family members in twenty countries.

Summary for Patent: 10,456,396

Title:	Dry eye treatments
Abstract:	Described herein are methods and pharmaceutical formulations for treating dry eye disease.
Inventor(s):	Douglas Michael Ackermann, JR., James LOUDIN, Kenneth J. Mandell
Assignee:	Oyster Point Pharma Inc
Application Number:	US15/422,382
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,456,396
Patent Claim Types: see list of patent claims	Use; Formulation; Device;

Drugs Protected by US Patent 10,456,396

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes			Y			TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

International Family Members for US Patent 10,456,396

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015336216
Australia	2020213351
Brazil	112017008097
Brazil	122022025737
Canada	2965129
China	107106542
China	111956650